References

Bensaid, M., M. Gary-Bobo, A. Esclangon, J.P. Maffrand, G. Le Fur, F. Oury-Donat and P. Soubrie, 2003. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol., 63: 908-914.
CrossRef  |  PubMed  |  Direct Link  |  

Despres, J.P., A. Golay and L. Sjostrom, 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl. J. Med., 353: 2121-2134.
Direct Link  |  

Doyon, C., R.G. Denis, E.D. Baraboi, P. Samson, J. Lalonde, Y. Deshaies and D. Richard, 2006. Effects of rimonnabant (SR141716) on fasting-induced hypothalamic pituitary adrenal axis and neuronal activation in lean and obese zucker rats. Diabetes, 55: 3403-3410.
PubMed  |  

Festuccia, W.T., M. Laplante, M. Berthiaume, Y. Gelinas and Y. Deshaies, 2006. PPARγ agonism increases rat adipose tissue lipolysis, expression of glyceride lipases and the response of lipolysis to hormonal control. Diabetologia, 49: 2427-2436.
PubMed  |  

Freedland, C.S., C.T. Whitlow, H.R. Smith and L.J. Porrino, 2003. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and-tolerant animals: A quantitative 2-[14C] deoxyglucose study. Brain Res., 962: 169-179.

Gary-Bobo, M., G. Elachouri, J.F. Gallas, P. Janiak and P. Marini et al., 2007. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats. Hepatologym, 46: 122-129.
PubMed  |  

Gomez, R., M. Navarro1, B. Ferrer, J.M. Trigo and A. Bilbao et al., 2002. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci., 22: 9612-9617.
Direct Link  |  

Guo, Y., G. Wu, X. Su, H. Yang and J. Zhang, 2009. Antiobesity action of a daidzein derivative on male obese mice induced by a high-fat diet. Nutr. Res., 29: 656-663.
PubMed  |  

Jeong, W.I., D. Osei-Hyiaman, O. Park, J. Liu and S. Batkai et al., 2008. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab., 7: 227-235.
PubMed  |  

Kojima, M., N. Kato, D. Hirano, T. Ochi, A. Nii, K. Shinjo and H. Eda, 2009. Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by concanavalin A. Hepatol Res., 39: 408-414.
PubMed  |  

Livak, K.J. and T.D. Schmittgen, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCT method. Methods, 25: 402-408.
CrossRef  |  Direct Link  |  

McKay, R.M., J.P. McKay, L. Avery and J.M. Graff, 2003. C. elegans: A model for exploring the genetics of fat storage. Dev. Cell, 4: 131-142.
PubMed  |  

McLaughlin, P.J., L. Qian, J.T. Wood, A. Wisniecki and K.M. Winston et al., 2006. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol. Biochem. Behav., 83: 396-402.
PubMed  |  

Nakamura, T., K. Tokunaga, I. Shimomura, M. Nishida and S. Yoshida et al., 1994. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis, 107: 239-246.
CrossRef  |  

Osei-Hyiaman, D., J. Liu, L. Zhou, G. Grezgorz and J. Harvey-White et al., 2008. Hepatic CB1 receptor is required for development of diet-induced steatosis dyslipidemia and insulin and leptin resistance in mice. J. Clin. Invest., 118: 3160-3169.
CrossRef  |  

Osei-Hyiaman, D., M. DePetrillo, P. Pacher, J. Liu and S. Radaeva et al., 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest, 115: 1298-1305.
CrossRef  |  PubMed  |  

Pang, J., Y. Choi and T. Park, 2008. Ilex paraguariensis extract ameliorates obesity induced by high-fat diet: Potential role of AMPK in the visceral adipose tissue. Arch. Biochem. Biophys., 476: 178-185.
PubMed  |  

Ragan, J.A., D.E. Bourassa, J. Blunt, D. Breen and F.R. Busch et al., 2009. Development of a practical and efficient synthesis of CP-945,598-01, a CB1 antagonist for the treatment of obesity. Org. Process Res. Dev., 13: 186-197.
CrossRef  |  

Ravinet, T.C., M. Arnone, C. Delgorge, N. Gonalons, P. Keane, J.P. Maffrand and P. Soubrie, 2003. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 284: 345-353.
PubMed  |  

Rinaldi-Carmona, M., F. Barth, M. Heaulme, D. Shire and B. Calandra et al., 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350: 240-244.
PubMed  |  

Serrano, A., I. Del-Arco, F. Javier-Pavon, M. Macias, V. Perez-Valero and F. Rodriguez-de-Fonseca, 2008. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in zucker rats. Neuropharmacol., 54: 226-234.
PubMed  |  

Shan, T., Y. Wang, T. Wu, J. Guo, J. Liu, J. Feng and Z. Xu, 2008. Porcine adipose triglyceride lipase complementary deoxyribomucleic acid clone, expression pattern and regulation by resveratrol. J. Anim. Sci., 86: 1781-1788.
CrossRef  |  Direct Link  |  

Sink, K.S., P.J. McLaughlin, J.A. Wood, C. Brown and P. Fan et al., 2008. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacol., 33: 946-955.
PubMed  |  

Sink, K.S., V.K. Vemuri, J. Wood, A. Makriyanni and J.D. Salamone, 2009. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: Effects on food-reinforced behavior and comparisons with AM4113. Pharmacol. Biochem. Behav., 91: 303-306.
PubMed  |  

Tedesco, L., A. Valerio, C. Cervino, A. Cardile and C. Pagano et al., 2008. Cannabinoid Type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes, 57: 2028-2036.
CrossRef  |  

Teixeira-Clerc, F., B. Julien, P. Grenard, J.T.V. Nhieu and V. Deveaux et al., 2006. CB1 cannabinoid antagonism: A new strategy for the treatment of liver fibrosis. Nat. Med., 12: 671-676.
CrossRef  |  

Van Gaal, L.F., A.M. Rissanen, A.J. Scheen, O. Ziegler and S. Rossner, 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365: 1389-1397.
PubMed  |  

Van Vleet, E.S., S. Candileri, J. McNeillie, S.B. Reinhardt, M.E. Conkright and A. Zwissler, 1984. Neutral lipid components of eleven species of caribbean sharks. Comp. Biochem. Physiol., 79: 549-554.
CrossRef  |  

Vickers, S.P., L.J. Webster, A. Wyatt, C.T. Dourish and G.A. Kennett, 2003. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology, 167: 103-111.
PubMed  |  

Wang, S., K.G. Soni, M. Semache, S. Casavant, M. Fortier, L. Pan and G.A. Mitchell, 2008. Lipolysis and the integrated physiology of lipid energy metabolism. Mol. Genet Metab., 95: 117-126.
PubMed  |  

Zurlo, F., K. Larson, C. Bogardus and E. Ravussin, 1990. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J. Clin. Invest., 86: 1423-1427.
CrossRef  |  Direct Link  |